Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies

Immunology

Volumn 133, Issue 2, 2011, Pages 239-245

  Pedersen, Anders E ^a   Jungersen, Mette B ^a   Pedersen, Charlotte D ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

B cell; CD20; Monocytes; Rituximab; Shaving

Indexed keywords

BENZYLSULFONYL FLUORIDE; EDETIC ACID; PROTEINASE; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CELL SURFACE; COCULTURE; ENDOCYTOSIS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKOCYTE CULTURE; LYMPHOCYTE CULTURE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELLS, CULTURED; FLOW CYTOMETRY; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKOCYTES, MONONUCLEAR; PEPTIDE HYDROLASES; PROTEIN BINDING;

EID: 79955020374     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03434.x     Document Type: Article

References (16)

1. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 2005; 54:11-29.
2. Fischer L, Penack O, Gentilini C et al. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells. Exp Hematol 2006; 34:753-9.
3. Golay J, Manganini M, Facchinetti V et al. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 2003; 88:1002-12.
4. Tedder TF, Baras A, Xiu Y. Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin Immunopathol 2006; 28:351-64.
5. Uchida J, Hamaguchi Y, Oliver JA et al. The innate mononuclear phagocytic network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199:1659-69.
6. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99:1314-9.
7. Nielsen CH, El Fassi D, Hasselbalch HC, Bendtzen K, Hegedüs L. B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther 2007; 7:1061-78.
8. Maloney DG, Grillo-López AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-95.
9. Huhn D, von Schilling C, Wilhelm M et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326-31.
10. Griffin FM, Griffin AM, Silverstein SC. Studies on the mechanism of phagocytosis: II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med 1976; 144:788-809.
11. Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181:8120-32.
12. Beum PV, Lindorfer MA, Taylor RP. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized daudi cells is promoted by NK cells and inhibited by monocytes due to shaving. J Immunol 2008; 181:2916-24.
13. Williams ME, Densmore JJ, Pawluczkowycz AW et al. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol 2006; 177:7435-43.
14. Beers SA, Chan CHT, James S et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112:4170-7.
15. Svane IM, Nikolajsen K, Walter MR et al. Characterization of monocyte-derived dendritic cells maturated with IFN-α. Scand J Immunol 2006; 63:217-22.
16. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176:2600-9.